Evidence map›Paper›PMID 31514052›Full record

ArticleRedox biology2020

Anticancer activity of a Gold(I) phosphine thioredoxin reductase inhibitor in multiple myeloma.

Jun Hui Sze, Prahlad V Raninga, Kyohei Nakamura, Mika Casey, Kum Kum Khanna, Susan J Berners-Price, Giovanna Di Trapani, Kathryn F Tonissen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Redox biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 66 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Mononuclear ηJournal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2024
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Jun Hui SzeSchool of Environment and Science, Griffith University, Nathan, QLD, 4111, Australia; Griffith Institute for Drug Discovery, Griffith University, Nathan, QLD, 4111, Australia.
Prahlad V RaningaSignal Transduction Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD, 4006, Australia.
Kyohei NakamuraImmunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD, 4006, Australia.
Mika CaseyImmunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD, 4006, Australia.
Kum Kum KhannaSignal Transduction Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD, 4006, Australia.
Susan J Berners-PriceInstitute for Glycomics, Griffith University, Southport, QLD, 4222, Australia.
Giovanna Di TrapaniSchool of Environment and Science, Griffith University, Nathan, QLD, 4111, Australia. Electronic address: g.ditrapani@griffith.edu.au.
Kathryn F TonissenSchool of Environment and Science, Griffith University, Nathan, QLD, 4111, Australia; Griffith Institute for Drug Discovery, Griffith University, Nathan, QLD, 4111, Australia. Electronic address: k.tonissen@griffith.edu.au.
Griffith University · AUQIMR Berghofer Medical Research Institute · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple myeloma (MM), the second most common haematological malignancy, is a clonal plasma B-cell neoplasm that forms within the bone marrow. Despite recent advancements in treatment, MM remains an incurable disease. Auranofin, a linear gold(I) phosphine compound, has previously been shown to exert a significant anti-myeloma activity by inhibiting thioredoxin reductase (TrxR) activity. A bis-chelated tetrahedral gold(I) phosphine complex [Au(d2pype)

Indexed as

AnimalsCell ProliferationCell SurvivalDown-RegulationGene Expression Regulation, NeoplasticGoldHumansMiceMice, Inbred NODMice, SCIDMultiple MyelomaPhosphinesProto-Oncogene Proteins c-mycThioredoxin-Disulfide ReductaseXenograft Model Antitumor AssaysGoldMYC protein, humanPhosphinesProto-Oncogene Proteins c-mycThioredoxin-Disulfide ReductaseApoptosisAuranofinGold(I) compoundsMultiple myelomaThioredoxinThioredoxin reductase

Identifiers

PMID31514052
PMCPMC6742860
OpenAlexW2970639571

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.